Evaluation of weekly escalating doses of dichloromethotrexate in patients with hepatocellular carcinoma and other solid tumors

Twenty-one patients with solid tumors were treated with weekly 6-h intravenous infusions of dichloromethotrexate (DCM), with escalating doses every other week. Frequently observed toxicities included leukopenia, thrombocytopenia, and mucositis. Nausea, vomiting, diarrhea, and elevation of hepatic en...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1982-01, Vol.8 (3), p.305
Main Authors: Tester, W J, Donehower, R C, Eddy, J L, Myers, C E, Ihde, D C
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic Agents - administration & dosage
Carcinoma, Hepatocellular - drug therapy
Drug Administration Schedule
Female
Humans
Liver Neoplasms - drug therapy
Male
Methotrexate - administration & dosage
Methotrexate - adverse effects
Methotrexate - analogs & derivatives
Methotrexate - metabolism
Middle Aged
Protein Binding
Serum Albumin - analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-one patients with solid tumors were treated with weekly 6-h intravenous infusions of dichloromethotrexate (DCM), with escalating doses every other week. Frequently observed toxicities included leukopenia, thrombocytopenia, and mucositis. Nausea, vomiting, diarrhea, and elevation of hepatic enzymes and bilirubin occurred less often. The toxicity of DCM was dose-dependent; the maximum tolerated dosage excalation plan was 400 mg/m2 x 2 weeks, 800 mg/m2 x 2 weeks, and then 1,200 mg/m2 weekly. Plasma concentrations of DCM were measured during 61 infusions and apparent half-lives determined. The plasma elimination of DCM appears to be similar to that of methotrexate. Three objective tumor responses seen in the seven hepatocellular carcinoma patients treated warrant further investigation.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00254055